18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy

[1] Boxer AL(2017)Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches Lancet Neurol 16 552-563

[2] Yu JT(2020)Distribution patterns of tau pathology in progressive supranuclear palsy Acta Neuropathol 140 99-119

[3] Golbe LI(2021)Validation of the new pathology staging system for progressive supranuclear palsy Acta Neuropathol 141 787-789

[4] Litvan I(2007)Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome Brain 130 1566-1576

[5] Lang AE(2020)Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD J Neuropathol Exp Neurol 79 296-304

[6] Höglinger GU(2022)In vivo J Nucl Med 63 1052-1057

[7] Kovacs GG(2020)F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy Brain 143 3477-3494

[8] Lukic MJ(2021)18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases Neuron 109 42-58.e8

[9] Irwin DJ(2017)High-contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies Mov Disord 32 853-864

[10] Arzberger T(2020)Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria Front Neurosci 14 604-2323

[1] Boxer AL(2017)Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches Lancet Neurol 16 552-563

[2] Yu JT(2020)Distribution patterns of tau pathology in progressive supranuclear palsy Acta Neuropathol 140 99-119

[3] Golbe LI(2021)Validation of the new pathology staging system for progressive supranuclear palsy Acta Neuropathol 141 787-789

[4] Litvan I(2007)Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome Brain 130 1566-1576

[5] Lang AE(2020)Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD J Neuropathol Exp Neurol 79 296-304

[6] Höglinger GU(2022)In vivo J Nucl Med 63 1052-1057

[7] Kovacs GG(2020)F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy Brain 143 3477-3494

[8] Lukic MJ(2021)18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases Neuron 109 42-58.e8

[9] Irwin DJ(2017)High-contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies Mov Disord 32 853-864

[10] Arzberger T(2020)Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria Front Neurosci 14 604-2323